Pfizer
Merck/Pfizer’s Bavencio wins slight reprieve after NICE nod
March 1, 2018Medical Communications, Sales and Marketing Bavencio, Merck, Pfizer, biotech, drugs, pharma, pharmaceutical
Just two weeks ago, Merck KGaA and Pfizer were hit with a major setback for their PD-L1 immunotherapy, Bavencio, after …
Pfizer taps real world evidence for CVD in new partnership
February 14, 2018Research and Development BC Platforms, Pfizer, biotech, cardiovascular disease, drugs, pharma, pharmaceutical
BC Platforms, a company that focuses on genomic data managements and analysis, has announced that it has partnered with Pfizer …
FDA approves Gilead’s Biktarvy for HIV as Viiv Healthcare launches patent lawsuit
February 8, 2018Sales and Marketing Biktarvy, FDA, GSK, Gilead, HIV, Pfizer, Shionogi, US, ViiV Healthcare, descovy, pharma
Gilead has announced that its daily single-tablet therapy Biktarvy has received FDA approval for HIV-1 infection.
Pfizer teams up with Indian Government to battle antimicrobial resistance
January 31, 2018Medical Communications, Research and Development India, Pfizer, antimicrobial resistance, pharma
Pfizer has entered into a partnership with the Indian Council of Medical Research (ICMR) in an effort to fight antimicrobial …
Pfizer’s Xalkori sees rejection at the hands of NICE in lung cancer
January 19, 2018Medical Communications, Sales and Marketing Cancer, NCIE, NSCLC, Pfizer, UK, Xalkori, lung cancer, pharma
UK regulator NICE has announced its decision not to recommend Pfizer’s Xalkori (crizotinib) for use on the NHS in the …
Top Ten most popular articles on Pharmafile.com this week
January 12, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, HIV, J&J, JJ, Johnson & Johnson, Pfizer, Shire, Teva, Xarelto, patient reported outcomes
The Xmas break is now a distant memory as we move further into January, and with another Friday comes another …
Novartis prises Pfizer’s Oncology Head away
January 11, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, Pfizer, biotech, drugs, pharma, pharmaceutical
Novartis has been looking to find someone to fill the shoes of Bruno Strigini since it was revealed that he …
Pfizer exits neuroscience R&D space
January 8, 2018Research and Development, Sales and Marketing Pfizer, biotech, drugs, pharma, pharmaceutical
Pfizer announced over the weekend that it would be backing out of research and development into the neuroscience area, abandoning …
Top Ten most popular articles on Pharmafile.com this week
January 5, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, J&J, JJ, NICE, Pfizer, Spark Therapeutics, Valeant, top ten
Happy New Year from Pharmafile.com! We hope the first week of 2018 hasn’t been too rough. To the surprise of …
Pfizer makes $830m drug discovery pact with Arvinas
January 4, 2018Research and Development, Sales and Marketing Arvinas, Pfizer, biotech, drugs, pharma, pharmaceutical
Arvinas has managed to secure another big pharma collaboration, after it announced that Pfizer had signed a research and licensing …
NICE to take another look at Pfizer’s leukaemia drug
January 2, 2018Manufacturing and Production, Sales and Marketing NICE, Pfizer, biotech, drugs, pharma, pharmaceutical
Back in August of 2017, NICE rejected Pfizer’s Besponsa on cost-effectiveness grounds and the pharma giant was not best pleased. …
Pfizer’s Bosulif scores US green light in leukaemia sub-type
December 21, 2017Sales and Marketing FDA, Pfizer, bosulif, leukaemia, leukemia, pharma
Pfizer has revealed that its tyrosine kinase inhibitor Bosulif (bosutinib) has been awarded marketing authorisation from the FDA in the …
MSD and Pfizer receive approval for combo diabetes therapy
December 21, 2017Sales and Marketing MSD, Pfizer, biotech, diabetes, drugs, pharma, pharmaceutical
MSD (known as Merck in North America) and Pfizer have announced that their sodium-glucose co-transporter 2 (SGLT2) inhibitor has received …
FDA approves Pfizer’s Xeljanz for psoriatic arthritis
December 18, 2017Sales and Marketing FDA, Pfizer, Xeljanz, pharma, psoriatic arthritis
Pfizer has revealed that the FDA has passed marketing approval for Xeljanz (tofacitinib) for the treatment of active psoriatic arthritis …
What will Pfizer do with its second Remicade biosimilar?
December 14, 2017Sales and Marketing Ixifi, Johnson & Johnson, Pfizer, Remicade, biosimilars, biotech, drugs, inflectra, pharma, pharmaceutical
Pfizer is now in the unusual position of owning two biosimilars to Johnson & Johnson’s Remicade, though one of these …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
